Centivax Inc, the therapeutics spinout of Contract Research Organization Distributed Bio Inc, announced today a licensing agreement with Thermo Fisher Scientific.
Thermo Fisher has developed and evaluated several variants of Centivax's highly specific and effective therapeutic antibody candidates against COVID-19 for use in research, including flow cytometry, histopathology, in vitro and in vivo neutralization, Luminex and ELISA applications. These products are now commercially available to academic and industry research laboratories.
Centivax's engineered antibodies have been validated for potency and efficacy both in vitro and in vivo, protecting an animal model of hamsters from SARS-CoV-2, the virus that causes COVID-19. Confirmed simultaneously at two independent national laboratories, the Centivax lead antibody was found to be effective both as a therapeutic for infected hamsters as well as a prophylactic (preventative) measure to protect hamsters from developing symptoms upon exposure to SARS-CoV-2.
"This is a tremendous opportunity for Centivax and our COVID-19 efforts," says Dr. Jacob Glanville, Founder, CEO, and President of Centivax and Distributed Bio. "Thermo Fisher Scientific is an unrivaled company in the scientific community. Licensing our antibodies globally allows laboratories across the planet to be empowered with new tools to defeat the coronavirus. We are confident this agreement is yet another referendum on the unique quality of our antibodies, enabling tools for research and new diagnostics while we at Centivax accelerate our antibody therapeutic through clinical trials and out to the world's hospitals."